2509447-08-7
Chemical Structure
Romlusevimab
Synonym(s): BRII-198
- CAS No.: 2509447-08-7
- Formula:N/A
- Molecular Weight:(145.126 kDa)
IUPAC Name: (4S,7S,10S,13S,16S,19R,22S,25S,28S,31S,34S,37S)-41-amino-4-((S)-6-amino-2-((S)-2,6-diaminohexanamido)hexanamido)-34-(4-aminobutyl)-37-carbamoyl-7-(carboxymethyl)-16,25-diethyl-31-(4-hydroxybenzyl)-22,28-bis(hydroxymethyl)-10,13-diisopropyl-19-(mercaptomethyl)-5,8,11,14,17,20,23,26,29,32,35-undecaoxo-6,9,12,15,18,21,24,27,30,33,36-undecaazahentetracontanoic acid
SMILES: [Romlusevimab]
Biological Activity: Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Romlusevimab | 95.00% | Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331. [Content Brief]
- [2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. [Content Brief]
Keywords
